Gregory M Landes

US Patent:

7655762, Feb 2, 2010

Filed:

Jan 6, 2006

Appl. No.:

11/327844

Inventors:

Gregory M. Landes - The Woodlands TX, US
Kyu Chung - Granger IN, US
Ling Chen - Blue Bell PA, US
Urvi Desai - The Woodlands TX, US
David Reed Powell - Houston TX, US
Seokjoo Hong - The Woodlands TX, US

Assignee:

Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

C07K 16/18

US Classification:

5303881, 5303879

Abstract:

Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

US Patent:

7935796, May 3, 2011

Filed:

Dec 6, 2007

Appl. No.:

12/001012

Inventors:

Gregory Landes - San Mateo CA, US
Seokjoo Hong - The Woodlands TX, US
Urvi Desai - The Woodlands TX, US
David Powell - Houston TX, US
Xiao Feng - The Woodlands TX, US

Assignee:

Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

C07K 16/26
C07K 16/00
C07K 16/46

US Classification:

53038824, 5303871, 5303879, 5303881, 53038815, 5303872

Abstract:

Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

US Patent:

8067544, Nov 29, 2011

Filed:

Mar 19, 2004

Appl. No.:

10/805177

Inventors:

Gregory M. Landes - The Woodlands TX, US
Francine Chen - San Francisco CA, US
Binyam Bezabeh - Oakland CA, US
Ian Foltz - Burnaby, CA
Kam Fai Tse - Clinton CT, US
Michael Jeffers - Branford CT, US
Mehdi Mesri - Branford CT, US
Gary Starling - Clinton CT, US
Peter Mezes - Old Lyme CT, US
Nikolia Khramtsov - Branford CT, US

Assignee:

Curagen Corporation - New Haven CT

International Classification:

C07K 16/00

US Classification:

5303871, 4241301

Abstract:

The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

US Patent:

8092796, Jan 10, 2012

Filed:

Dec 4, 2009

Appl. No.:

12/631598

Inventors:

Gregory M. Landes - The Woodlands TX, US
Kyu Chung - Granger IN, US
Ling Chen - Blue Bell PA, US
Urvi Desai - The Woodlands TX, US
David Reed Powell - Houston TX, US
Seokjoo Hong - The Woodlands TX, US

Assignee:

Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

C07K 16/18
A61K 39/395

US Classification:

4241301, 5303879, 5303881, 4241391, 4241411, 4241421, 4241331

Abstract:

Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

US Patent:

8362211, Jan 29, 2013

Filed:

Dec 30, 2011

Appl. No.:

13/341860

Inventors:

Kathleen Ann Elias - San Francisco CA, US
Gregory Landes - San Bruno CA, US
Shweta Singh - South San Francisco CA, US
Wouter Korver - South San Francisco CA, US
Andrew Walling Drake - South San Francisco CA, US
Mary Haak-Frendscho - San Francisco CA, US
Gyorgy Pal Snell - San Francisco CA, US
Vinay Bhaskar - San Francisco CA, US

Assignee:

Takeda Pharmaceutical Company Limited - Osaka

International Classification:

C07K 16/18
C07K 16/28
C07K 16/40
C12P 21/08

US Classification:

5303871, 5303873, 53038822, 53038826, 4241301, 4241331, 4241411, 4241431

Abstract:

Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.

US Patent:

8591891, Nov 26, 2013

Filed:

Dec 8, 2011

Appl. No.:

13/315027

Inventors:

Gregory M. Landes - The Woodlands TX, US
Kyu Chung - Granger IN, US
Ling Chen - Blue Bell PA, US
Urvi Desai - The Woodlands TX, US
David Reed Powell - Houston TX, US
Seokjoo Hong - The Woodlands TX, US

Assignee:

Lexicon Pharmaceuticals, Inc. - The Woodlands TX

International Classification:

A61K 39/395
C07K 16/18

US Classification:

4241301, 4241391, 4241411, 4241421, 4241331, 5303879, 5303881

Abstract:

Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

US Patent:

20020146693, Oct 10, 2002

Filed:

Feb 1, 2001

Appl. No.:

09/773861

Inventors:

Gregory Landes - Livermore CA, US

International Classification:

C12Q001/68
C07H021/04
A61K048/00

US Classification:

435/006000, 514/044000, 536/023200, 536/024300, 435/320100

Abstract:

The present invention provides a method for isolating, identifying and cataloging partial messenger RNAs (mRNAs) or gene tags correlating to secreted and non-secreted proteins in a cell or tissue sample. The method requires obtaining a polynucleotide from a cellular homogenate, wherein the polynucleotide encodes the polypeptide and determining the sequence of the polynucleotide and its expression level. In essence, the method consists of two phases: (1) enrichment/purification of membrane-bound mRNA, and (2) sequence analysis. Neither of these processes, if performed independently of each other, would enable specific and rapid identification and enumeration of transcripts that encode secreted proteins and integral membrane bound proteins. This invention also provides computer-related systems and methods. More specifically, the invention provides a system and method for automatically generating a data base of gene tags corresponding to secreted and non-secreted proteins from cell or tissue samples and using the data base for filtering the tag counts from the samples into meaningful candidates for further testing and analysis.

US Patent:

20030211522, Nov 13, 2003

Filed:

Jan 17, 2003

Appl. No.:

10/346514

Inventors:

Gregory Landes - Livermore CA, US
Lesley Michalowsky - Sudbury MA, US
Glenn Miller - Hopkinton MA, US
William Weber - Franklin MA, US

International Classification:

C12Q001/68
C12P019/34

US Classification:

435/006000, 435/091200

Abstract:

The present invention provides non-invasive methods to distinguish fetal DNA from maternal DNA and thereby detect fetal aneuploidies and alleles. The methods require isolation of fetal DNA from maternal serum and treatment with a reagent that creates primary sequence differences between maternal and fetal DNA that exhibit differential methylation. Various methods including quantitative PCR is used to identify detect fetal aneuploidies and alleles. In one embodiment, the method is useful to identify imprinting genes in subjects, including adults.